In a special meeting Aug. 11, shareholders of CardioDynamics approved the company’s merger with hand-carried ultrasound pioneer SonoSite.
CardioDynamics set to join SonoSite
In a special meeting Aug. 11, shareholders of CardioDynamics approved the company’s merger with hand-carried ultrasound pioneer SonoSite. Under the $10 million cash deal, they will receive $1.35 per share, representing a 69% premium over the closing share price on June 8, 2009, the day before the definitive merger agreement was announced. The shareholder vote clears the way for CardioDynamics, which makes the BioZ impedance cardiography technology, to join SonoSite as a wholly owned subsidiary. The technology helps diagnose and assess high blood pressure and ventricular function.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.